Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2001

View Archived Issues

Abgenix reports 2000 highlights and goals for 2001

OP-1 receives positive and negative opinions from regulatory authorities

ExonHit Therapeutics expands operations and scope

Peptide Therapeutics consolidates operations and changes name

MTC-DOX assigned orphan drug status for liver cancer Rx by FDA

PK/PD modeling following single oral doses of NN-703

CytRx and University of Cincinnati to investigate CRL-5861 for muscular dystrophy

NIAID grant awarded to Aphios for development of HIV vaccine adjuvant

Newly discovered protein may have major impact on bacterial resistance

Testosterone progressive hydration buccal tablets show promise in phase III

Preparation and antitumor activity of new xanthone compound from Asta Medica

Abbott's new ketolide derivatives display potent and broad-spectrum antibacterial activity

Two new series of vitronectin receptor antagonists particularly useful in osteoporosis

Femara receives E.U. approval as first-line breast cancer therapy

COX-2 inhibitors as antiinflammatory, analgesic agents presented by Pfizer

New matrix metalloproteinase inhibitors show potential in arthritis

Patent assigned to Warner-Lambert covers MMP inhibitors for various disorders

New peptoid MMP inhibitors useful for cancer, etc.

Arena and Taisho expand obesity orphan receptor research agreement

FTC consent decree relating to GSK merger finalized

Pherin cleared to begin clinical trials of antianxiety compound

Neuron Therapeutics begins phase I trial with novel stroke therapy

Trisenox moves into multiple myeloma clinical trials

Oral sodium tungstate reduces hyperglycemia and hypertriglyceridemia in ZDF rats

Novogen phase I trial of anticancer drug phenoxodiol approved by FDA

CroFab now available in the U.S. for treatment of poisonous snakebites

Sedecim Therapeutics: a new company focusing on IL-16-related therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...